Crucell and DSM Announce PER.C6® Licensing Agreement with Chiron

18-Aug-2005

Crucell N.V. and allied contract manufacturer DSM Biologics announced that they have signed a PER.C6® research license agreement for recombinant protein production with Chiron Corporation. This new agreement allows Chiron to evaluate the PER.C6® cell line for use in the manufacturing of Chiron's prophylactic hepatitis C vaccine, which is currently in phase I clinical trials. Financial details were not disclosed.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance